Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives.
Heyrman B, Meers S, Sid S, Put N, Theunissen K, Van Eygen K, De Beule N, Clauwaert M, Maes H, Salembier A, Lemmens J, Velde AV, Selleslag D, Bouziotis J, De Becker A, Anguille S.
Heyrman B, et al. Among authors: de becker a.
EJHaem. 2024 Oct 4;5(5):1096-1099. doi: 10.1002/jha2.1027. eCollection 2024 Oct.
EJHaem. 2024.
PMID: 39415916
Free PMC article.
No abstract available.